The Globe and Mail reports in its Friday, May 29, edition that Canaccord Genuity analyst Neil Maruoka expects long-term organic growth for Valeant Pharmaceuticals International ($241.73 (U.S.)) will lead to "upward earnings revisions." The Globe's David Leeder writes in the Eye On Equities column that though Mr. Maruoka touted the "blockbuster potential" of the Xifaxan, an irritable bowel syndrome drug (IBSD), he feels the impact of the product is already priced into the stock. Mr. Maruoka says: "The drug is already close to a $1-billion run rate from the current two indications in hepatic encephalopathy and traveler's diarrhea, and we believe the IBSD market should easily support an incremental greater than $1-billion opportunity. ... On the competitive front, Actavis' eluxadoline was also approved for the same indication. ... However, we think the market is more than sufficient to support two drugs, as Xifaxan presents several key advantages versus its competitor." While maintaining his "buy" recommendation, Mr. Maruoka increased his price target to $275 (U.S.) from $250 (U.S.) after adjusting his forecasts to reflect a reduced regulatory risk. Analysts on average target the shares at $237.20 (U.S.).